These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

690 related articles for article (PubMed ID: 28796017)

  • 1. Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.
    Elliott JA; Doyle SL; Murphy CF; King S; Guinan EM; Beddy P; Ravi N; Reynolds JV
    Ann Surg; 2017 Nov; 266(5):822-830. PubMed ID: 28796017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy.
    Panje CM; Höng L; Hayoz S; Baracos VE; Herrmann E; Garcia Schüler H; Meier UR; Henke G; Schacher S; Hawle H; Gérard MA; Ruhstaller T; Plasswilm L;
    Radiat Oncol; 2019 Sep; 14(1):166. PubMed ID: 31511012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Skeletal Muscle Mass During Neoadjuvant Chemoradiotherapy Predicts Postoperative Mortality in Esophageal Cancer Surgery.
    Reisinger KW; Bosmans JW; Uittenbogaart M; Alsoumali A; Poeze M; Sosef MN; Derikx JP
    Ann Surg Oncol; 2015 Dec; 22(13):4445-52. PubMed ID: 25893413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Skeletal Muscle Loss and Sarcopenia on Outcomes of Locally Advanced Esophageal Cancer during Neoadjuvant Chemoradiation.
    Xiao X; Fang PH; Zhou JF; Li XK; Shang QX; Yang YS; Luan SY; Chen LQ; Yuan Y
    Ann Surg Oncol; 2024 Jun; 31(6):3819-3829. PubMed ID: 38245646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer.
    Paireder M; Asari R; Kristo I; Rieder E; Tamandl D; Ba-Ssalamah A; Schoppmann SF
    Eur J Surg Oncol; 2017 Feb; 43(2):478-484. PubMed ID: 28024944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes With Open and Minimally Invasive Ivor Lewis Esophagectomy After Neoadjuvant Therapy.
    Tapias LF; Mathisen DJ; Wright CD; Wain JC; Gaissert HA; Muniappan A; Lanuti M; Donahue DM; Morse CR
    Ann Thorac Surg; 2016 Mar; 101(3):1097-103. PubMed ID: 26652140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarcopenia is a Predictor of Postoperative Respiratory Complications in Patients with Esophageal Cancer.
    Ida S; Watanabe M; Yoshida N; Baba Y; Umezaki N; Harada K; Karashima R; Imamura Y; Iwagami S; Baba H
    Ann Surg Oncol; 2015 Dec; 22(13):4432-7. PubMed ID: 25862583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multimodal treatment of locally advanced esophageal adenocarcinoma: which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients.
    Hoeppner J; Zirlik K; Brunner T; Bronsert P; Kulemann B; Sick O; Marjanovic G; Hopt UT; Makowiec F
    J Surg Oncol; 2014 Mar; 109(3):287-93. PubMed ID: 24277235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center.
    Reynolds JV; Donohoe CL; McGillycuddy E; Ravi N; O'Toole D; O'Byrne K; Hollywood D
    J Thorac Cardiovasc Surg; 2012 May; 143(5):1130-1137.e1. PubMed ID: 22244551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of measurement of skeletal muscle mass on clinical outcomes in patients with esophageal cancer undergoing esophagectomy after neoadjuvant chemotherapy.
    Ishida T; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Motoori M; Kimura Y; Nakajima K; Mori M; Doki Y
    Surgery; 2019 Dec; 166(6):1041-1047. PubMed ID: 31607486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes.
    Tegels JJ; van Vugt JL; Reisinger KW; Hulsewé KW; Hoofwijk AG; Derikx JP; Stoot JH
    J Surg Oncol; 2015 Sep; 112(4):403-7. PubMed ID: 26331988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Timing of esophagectomy in multimodal therapy of esophageal cancer: Impact of time interval between neoadjuvant therapy and surgery on outcome and response].
    Müller AK; Lenschow C; Palmes D; Senninger N; Hummel R; Lindner K
    Chirurg; 2015 Sep; 86(9):874-80. PubMed ID: 25662991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer.
    Vallböhmer D; Hölscher AH; DeMeester S; DeMeester T; Salo J; Peters J; Lerut T; Swisher SG; Schröder W; Bollschweiler E; Hofstetter W
    Ann Surg; 2010 Nov; 252(5):744-9. PubMed ID: 21037429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcopenia as a predictor of pulmonary complications after esophagectomy for thoracic esophageal cancer.
    Nishigori T; Okabe H; Tanaka E; Tsunoda S; Hisamori S; Sakai Y
    J Surg Oncol; 2016 May; 113(6):678-84. PubMed ID: 26936808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemoradiotherapy for Patients with cT3/Nearly T4 Esophageal Cancer: Is Sarcopenia Correlated with Postoperative Complications and Prognosis?
    Saeki H; Nakashima Y; Kudou K; Sasaki S; Jogo T; Hirose K; Edahiro K; Korehisa S; Taniguchi D; Nakanishi R; Kubo N; Ando K; Kabashima A; Oki E; Maehara Y
    World J Surg; 2018 Sep; 42(9):2894-2901. PubMed ID: 29488065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcopenia as a predictor of poor surgical and oncologic outcomes after abdominal surgery for digestive tract cancer: A prospective cohort study.
    Zhang S; Tan S; Jiang Y; Xi Q; Meng Q; Zhuang Q; Han Y; Sui X; Wu G
    Clin Nutr; 2019 Dec; 38(6):2881-2888. PubMed ID: 30630709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer.
    Motoori M; Fujitani K; Sugimura K; Miyata H; Nakatsuka R; Nishizawa Y; Komatsu H; Miyazaki S; Komori T; Kashiwazaki M; Iwase K; Yano M
    Oncology; 2018; 95(5):281-287. PubMed ID: 30149394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-dependent survival impact of body mass index in patients with oesophageal squamous cell carcinoma.
    Sugawara K; Yamashita H; Okumura Y; Yagi K; Aikou S; Seto Y
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1948-1955. PubMed ID: 32654887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival Benefit of Neoadjuvant Treatment in Clinical T3N0M0 Esophageal Cancer: Results From a Retrospective Multicenter European Study.
    Mantziari S; Gronnier C; Renaud F; Duhamel A; Théreaux J; Brigand C; Carrère N; Lefevre JH; Pasquer A; Demartines N; Collet D; Meunier B; Mariette C;
    Ann Surg; 2017 Nov; 266(5):805-813. PubMed ID: 28742698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.